* known hypersensitivity or allergic reactions to 4-aminoquinoline compounds or its ingredients. * current, or history of, ocular macular disease or retinal damage. * current, or history of, subnormal glomerular filtration. * current use of tamoxifen citrate. * current, or history of, cardiomyopathy, atrial, nodal, or ventricular arrhythmias, torsades de pointes, conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy. * subjects taking other drugs that have the potential to prolong qt interval if taken with hcq.

* known hypersensitivity or allergic reactions to 4-aminoquinoline compounds or its ingredients. * current, or history of, ocular macular disease or retinal damage. * current, or history of, subnormal glomerular filtration. * current use of tamoxifen citrate. * current, or history of, cardiomyopathy, atrial, nodal, or ventricular arrhythmias, torsades de pointes, conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy. * subjects taking other drugs that have the potential to prolong qt interval if taken with hcq.

- known hypersensitivity or allergic reactions to 4-aminoquinoline compounds or its ingredients. - current, or history of, ocular macular disease or retinal damage. - current, or history of, subnormal glomerular filtration. - current use of tamoxifen citrate. - current, or history of, cardiomyopathy, atrial, nodal, or ventricular arrhythmias, torsades de pointes, conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy. - subjects taking other drugs that have the potential to prolong qt interval if taken with hcq.

- known hypersensitivity or allergic reactions to 4-aminoquinoline compounds or its ingredients. - current, or history of, ocular macular disease or retinal damage. - current, or history of, subnormal glomerular filtration. - current use of tamoxifen citrate. - current, or history of, cardiomyopathy, atrial, nodal, or ventricular arrhythmias, torsades de pointes, conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy. - subjects taking other drugs that have the potential to prolong qt interval if taken with hcq.